Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Big pharmas are watching us closely!
View:
Post by Lesalpes29 on Jun 26, 2022 5:46pm

Big pharmas are watching us closely!

Fir sure : https://www.fiercebiotech.com/biotech/ma-down-big-pharma-likely-line-multiple-shots-goal-heading-2nd-half
Comment by Lesalpes29 on Jun 26, 2022 5:47pm
For sure! Of course!
Comment by gojotv! on Jun 27, 2022 1:26am
Agreed. In fact, I believe that Big Pharmas have agents on this board trying to convince shareholders to sell to them cheap. There's something called an "anchoring bias" where a buyer will start the bidding at a ridiculously low number to keep the ultimate selling price down. I've seen that a lot on these boards, with pundits talking about a fast sell-out as soon as clear ...more  
Comment by ScienceFirst on Jun 27, 2022 8:02am
Ask yourself if the acquisitions were able to destroy late-stage solid tumors?  The answer is no. Then, add this ability to do it with only a 2-doses treatment, with no side effects, all this with a standalone   treatment that doesn't need adjuvants.  Then, fix your valuation, to better assess the magnitude of the task.   Bristol Myers Squibb’s $4 billion ...more  
Comment by ScienceFirst on Jun 27, 2022 8:13am
Imagine the upfront $$$ to access to our technology. If we're to become a future SOC, our Ph. 2 data will be valued extremely high, when you see a perspective like below, as our first successful indication would di facto confirm the huge potential of our ACT platform. GSK has responded by inking a deal to buy privately held Affinivax for $2.1 billion upfront and two $600 million ...more  
Comment by ScienceFirst on Jun 27, 2022 8:17am
  There were some interesting deals in the half, particularly Pfizer’s $11.6 billion check for a chunk of Biohaven Pharmaceuticals. The New York Big Pharma carved out Biohaven’s migraine franchise while leaving some earlier-stage assets under the biotech’s purview.
Comment by Legit62 on Jun 27, 2022 8:33am
SF, if we get good news on Vaccine front, it will really add to our value, besides the fact that we destroy tumors, safely, cost efficient, and minimal treatments compared to rivals
Comment by Eoganacht on Jun 27, 2022 10:02am
Theralase's treatment destroys tumours completely, and that safely...how many anti-cancer drugs only shrink tumours at best? TLD1433 pdt should be a useful addition to most anti-cancer regimens to get the situation under control. What is a treatment like that worth? Should we just add up the cancer indications it's good for and multiply by a few billion?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250